Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

Sponsor
Community Cancer Care (Other)
Overall Status
Unknown status
CT.gov ID
NCT00300001
Collaborator
Amgen (Industry)
300
3
100

Study Details

Study Description

Brief Summary

The primary research objective of this protocol is to evaluate the impact of integrating a home-based symptom monitoring system in the day-to-day care of cancer patients in community settings on the frequency of supportive symptom interventions, symptom severity, and quality of life.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Patients will be randomly assigned to one of two groups. One group will be offered an Internet assisted home-based symptom reporting system Cancer Symptom Monitor (CSM) for a twelve-month study period. Patient and care team evaluations will be measured using quantitative and qualitative methods (via focus groups). The second group will receive "standard care" without home-based symptom monitoring. Both groups will be evaluated at baseline, 1, 2, 3, 6, 9, & 12 months, for symptom levels and overall quality of life during the twelve-month study period.

    Study Design

    Study Type:
    Observational
    Observational Model:
    Defined Population
    Time Perspective:
    Prospective
    Official Title:
    Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes
    Study Start Date :
    Mar 1, 2006

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:

      18 years old or older Diagnosis of solid tumor or hematologic malignancy Starting active treatment (chemotherapy or hormonal therapy) Must be able to give informed consent & consent to use the Cancer Symptom Monitor -

      Exclusion Criteria:

      Inability to give informed consent Life expectancy of less than 3 months Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Quality Oncology Care, Inc. Indianapolis Indiana United States 46202
      2 Community Regional Cancer Center-Community Hospital North Indianapolis Indiana United States 46256
      3 Morgan Hospital and Medical Center Martinsville Indiana United States 46151

      Sponsors and Collaborators

      • Community Cancer Care
      • Amgen

      Investigators

      • Principal Investigator: Dale E. Theobald, PhD, MD, Community Cancer Care, Inc.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00300001
      Other Study ID Numbers:
      • 2005-0186
      First Posted:
      Mar 7, 2006
      Last Update Posted:
      Aug 25, 2006
      Last Verified:
      Aug 1, 2006

      Study Results

      No Results Posted as of Aug 25, 2006